417 related articles for article (PubMed ID: 34775781)
1. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC
Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC; Sattar N; Rosenstock J; Ramasundarahettige C; Pratley R; Lopes RD; Lam CSP; Khurmi NS; Heenan L; Del Prato S; Dyal L; Branch K;
N Engl J Med; 2021 Sep; 385(10):896-907. PubMed ID: 34215025
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Gerstein HC; Li Z; Ramasundarahettige C; Baek S; Branch KRH; Del Prato S; Lam CSP; Lopes RD; Pratley R; Rosenstock J; Sattar N
Circulation; 2023 Mar; 147(13):1004-1013. PubMed ID: 36802715
[TBL] [Abstract][Full Text] [Related]
4. Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
Gerstein HC; Branch K; Heenan L; Del Prato S; Khurmi NS; Lam CSP; Pratley R; Rosenstock J; Sattar N
Diabetes Obes Metab; 2021 Feb; 23(2):318-323. PubMed ID: 33026143
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
Neves JS; Borges-Canha M; Vasques-Nóvoa F; Green JB; Leiter LA; Granger CB; Carvalho D; Leite-Moreira A; Hernandez AF; Del Prato S; McMurray JJV; Ferreira JP
J Am Coll Cardiol; 2023 Aug; 82(6):517-525. PubMed ID: 37532422
[TBL] [Abstract][Full Text] [Related]
6. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
7. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
9. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Rosenstock J; Sorli CH; Trautmann ME; Morales C; Wendisch U; Dailey G; Hompesch M; Choi IY; Kang J; Stewart J; Yoon KH
Diabetes Care; 2019 Sep; 42(9):1733-1741. PubMed ID: 31320446
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
11. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Kadowaki T; Yamamoto F; Taneda Y; Naito Y; Clark D; Lund SS; Okamura T; Kaku K
Expert Opin Drug Saf; 2021 Jun; 20(6):707-720. PubMed ID: 33706621
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
14. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
15. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
Al-Ozairi E; Narula K; Miras AD; Taghadom E; Samad AE; Al Kandari J; Alyosef A; Mashankar A; Al-Najim W; le Roux CW
Trials; 2024 Feb; 25(1):129. PubMed ID: 38365744
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
18. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
